Fueling Growth in Scary Times: Strategies improving MA viability, simultaneously providing accretive growth prospects
- psawhney09
- Jun 8, 2024
- 22 min read
TABLE OF CONTENTS:
13) Conclusion:
Introduction:
ENTERS BOARD ROOM →
“ EPS GROWTH, EPS GROWTH, EPS GROWTH, EPS GROWTH, EPS GROWTH!
….ok after this bathroom break, back to EPS convo, team!”
< INTERMISSION >
...Okay, no one can deny this is a tumultuous time to be a Medicare Advantage managed care plan OR provider group accepting MA patients. What used to be a cash cow vis-a-vis margin and cash flow, has now gone through the following:
Pandemic subsidies and exemptions have been pulled back
Pandemic monies were built into budget operations; without, plans are cutting back all spending the best they can
Stars measures and respective scores dropped for many
Weightings increased for harder to managed measures
New measures involving health equity represent headwinds as most are not remotely prepared
Risk adjustment program dropped the FFS multiplier (among other making reimbursement rates drop for plans
Some almost lost 10% of their monthly capitated payments
Part D - which essentially provided plan profits and subsidized part C is SLAMMED
This new $2,000 deductible max will leave plans without negotiating leverage or LITERALLY owning the PBM are scrambling
GLP-1 drugs are great in the sense that obesity is a disease….but the exorbitant costs are not sustainable even though its clear their use will continue to grow exponentially
Drug costs are anticipated to rise significantly. A study from the Journal of the American Medical Association found that prescription drug prices have increased by an average of 9.7% annually from 2008 to 2016.
In the past decade drug costs have risen 50%!
1 in 5 adults with mental drugs and 85% with chronic disease
Thousands of other tiny cuts that have left the upcoming rebate reallocation process the most precarious EVER
Some could have to reallocate (not $2 PMPM but values like an untenable ~$40 PMPM)
A more competitive environment than ever with minimal benefit-level differentiation opportunities and organizations willing to land-grab to snuff out the small players (e.g. DSNP PPOs!)
More compliance rules EVERY year
More stringent UM regulations among others leading to providers (like Mayo) not entertaining MA patients any further...
….and I’m probably missing more….
< INTERMISSION END >
….So now back to our boardroom…
Board Member 1 - “EPS GROWTH, EPS GROWTH, EPS GROWTH, EPS GROWTH, EPS GROWTH!
Ideas anyone besides more opex cuts and consolidation?”
“Preet! - What about M&A as our growth strategy in this environment? But no, no, no….not giant deals (*cough* cough Signify, Oak Street, etc.), '
I’m referencing long-standing companies that have steady revenue, brand equity, proven resilience/governance and might even improve balance sheet ratios!”
...we characterize aforementioned strategy below and break it apart into framework and value drivers -->
Moving past my colorful story-telling hypothetical, this strategy would be characterized by the following:
Targeting companies with long-dated revenue streams
Immediate & accretive deal economics delivered by:
Immediate boost to acquirer top line
Income generated improves financial profile, cash flow, and can even reduce revenue risk for acquirers in industries with cyclical or unpredictable revenue patterns
Revenue risk diversification creates resilience to economic uncertainty
Accretive economics allows for financial engineering opportunities including but not limited to: debt financing, capital structure optimization, tax benefits from acquisition, EPS accretion possibility, etc,
Upsell opportunities & cost synergies
Embracing the value of Non-Vertical Integration
"Sweat equity value"
(we dive even deeper into these value generators below)
In essence I am proposing a strategy that has been used by many – so not nothing new butttttt maybe de-prioritized in board rooms in favor of blockbuster deals that have massive integration workloads and add untenable amounts of leverage to balance sheets?
I am simply proposing that in these difficult times, this strategy may enable charged growth during uncertainty, and come with a plethora of tools to generate shareholder value and EPS growth. Sure that big blockbuster deal fell apart, changing your 10-year outlook. BUT stack a couple of these immediately tangible, value additive transactions together and see how fast your growth opportunities multiply!
Value creation opportunity unpacked:
Let’s start by explaining how each of the levers I mentioned can/will create meaningful value:
Access to Long-Dated Revenue Streams: Acquiring a company with established, long-dated revenue streams provides you with a steady income that can immediately contribute to your bottom line. Instead of starting from scratch to build these revenue streams, you're essentially buying a shortcut to revenue stability. This can be particularly beneficial if your company operates in industries with cyclical or unpredictable revenue patterns.
Accretive Value Economics: By carefully selecting acquisition targets with strong fundamentals, growth potential, and strategic fit, you can create value that exceeds the sum of individual parts. Through synergies, cost savings, revenue enhancements, and operational improvements, M&A transactions can be accretive to earnings per share (EPS), shareholder value, and overall company performance. This accretive value economics can drive stock price appreciation, attract investors, and strengthen your competitive position in the market.
Non-Vertical Integration: Unlike traditional vertical integration, where a company acquires suppliers or distributors to gain control over its supply chain, acquiring companies with complementary products, services, or market segments can be equally—if not more—beneficial. Non-vertical integration allows you to broaden your market reach, diversify your revenue streams, and capture new customer segments without taking on the risks associated with integrating upstream or downstream operations.
Sweat Equity Potential: While the acquired company might not have fully optimized its operations or realized its full potential, you see the opportunity to apply your expertise, resources, and management skills to unlock additional value. By injecting "sweat equity" into the acquired company, you can enhance its performance, streamline operations, and maximize profitability. This approach allows you to capitalize on synergies and efficiencies that might not have been achievable on your own. Instead of merely focusing on reducing costs, companies should aim for value creation through innovative practices and strategic synergies. For instance, the document highlights how applying expertise and resources to acquired companies can unlock additional value through operational improvements and revenue enhancements.
In essence, M&A offers a strategic avenue for growth by leveraging external opportunities to complement and enhance your existing capabilities. By acquiring companies with long-dated revenue streams, potential for sweat equity, and strategic alignment, you can fuel your growth strategy and create significant value for your organization and stakeholders.
Why not the blockbuster deal(s)?:
Opting for many long-dated revenue companies (they don't even need to be other payers or provider groups but can be goods & service manufacturers/benenfit managers) rather than one large one can be a strategic choice depending on your growth objectives, risk appetite, and market dynamics.
Here's why you might consider this approach:
Diversification: Acquiring multiple companies with long-dated revenue streams diversifies your risk. If one company faces challenges or market downturns, the impact on your overall portfolio is mitigated by the performance of other acquisitions. Diversification can enhance stability and resilience in your growth strategy, reducing the dependence on any single revenue source or market segment.
Scalability: Building a portfolio of long-dated revenue companies allows for scalability and flexibility in your growth trajectory. You can incrementally add acquisitions over time, gradually expanding your market presence, product offerings, and revenue streams. This phased approach enables you to manage integration complexities, assess performance, and refine your strategy iteratively.
Market Penetration: Acquiring multiple smaller companies with long-dated revenue streams can enable broader market penetration compared to a single large acquisition. By targeting companies operating in different geographic regions, niche markets, or customer segments, you can access diverse customer bases and capture opportunities that might be overlooked by larger competitors. This approach strengthens your market position and reduces competitive threats.
Innovation and Agility: A portfolio of smaller acquisitions fosters innovation and agility within your organization. Each acquisition brings unique capabilities, technologies, and perspectives that contribute to your overall innovation ecosystem. By integrating diverse talent pools and entrepreneurial cultures, you can adapt quickly to market changes, explore new business models, and stay ahead of evolving customer needs.
Value Creation Potential: While a single large acquisition may offer immediate scale and synergies, a portfolio of smaller acquisitions can create value over the long term through continuous optimization and strategic alignment. By actively managing and nurturing each acquired company, you can unlock incremental value, capitalize on emerging opportunities, and drive sustained growth and profitability.
In summary, opting for multiple long-dated revenue companies aligns with a strategy focused on diversification, scalability, market penetration, innovation, and long-term value creation. While a large acquisition may offer certain advantages, the portfolio approach provides resilience, agility, and a broader platform for sustainable growth in dynamic and competitive markets.
So like Thornbuster’s “Outsiders”?:
Yes, William N. Thorndike's book "The Outsiders: Eight Unconventional CEOs and Their Radically Rational Blueprint for Success" indeed provides insight into a strategy that aligns with the approach of acquiring multiple companies with long-term revenue streams.
Thorndike's book explores the unconventional strategies employed by eight CEOs who outperformed their peers by a significant margin over several decades.
One common thread among these CEOs was their emphasis on capital allocation and the pursuit of acquisitions as a means to drive value creation.
While the specific strategies of the CEOs profiled in "The Outsiders" varied, many of them exhibited a preference for acquisitions that offered long-term growth potential, strong cash flows, and opportunities for operational improvement.
Rather than pursuing large, transformative deals, these CEOs often sought out smaller, niche companies with sustainable revenue streams and the potential for significant upside.
By acquiring multiple companies with these characteristics, these CEOs were able to diversify their businesses, expand into new markets, and capitalize on opportunities that may have been overlooked by their competitors. This approach enabled them to create value for their shareholders over the long term and
achieve exceptional performance relative to their peers.
In essence, "The Outsiders" provides empirical evidence that aligns with the strategy of acquiring many long-dated revenue companies as a means to drive growth and create shareholder value. Thorndike's insights underscore the importance of disciplined capital allocation and strategic acquisitions in achieving sustainable success in the business world.
So like Thornbuster’s “Outsiders”?:
(Part Two - 'the skepticism'):
I understand skepticism. While William N. Thorndike's book "The Outsiders" primarily focuses on the unconventional strategies and capital allocation techniques of eight CEOs who achieved exceptional long-term success, it doesn't explicitly delve into the specific strategy of acquiring multiple companies with long-dated revenue streams as a core theme.
"The Outsiders" primarily highlights the importance of capital allocation decisions such as share buybacks, dividends, and acquisitions in driving shareholder value. The CEOs profiled in the book often pursued acquisitions that represented attractive opportunities to deploy capital effectively and generate substantial returns over time. However, the book does not extensively discuss the strategy of acquiring multiple long-dated revenue companies as a distinct approach.
So, while the principles of disciplined capital allocation and strategic acquisitions discussed in "The Outsiders" may align with aspects of the strategy you mentioned, the book itself does not serve as direct proof of that particular strategy. It's essential to analyze Thorndike's insights within the context of his broader discussion on effective capital allocation and value creation in business.
This sounds like another Valeant Debacle, no?:
The case of Valeant Pharmaceuticals serves as a cautionary tale highlighting the risks and pitfalls associated with aggressive acquisition strategies, particularly when pursued without adequate diligence, transparency, and long-term sustainability considerations.
Over-reliance on Acquisitions: Valeant's growth strategy was heavily dependent on acquisitions, often acquiring companies at a rapid pace and financing these transactions with significant debt. This aggressive approach led to concerns about the company's ability to integrate acquired businesses effectively and manage the resulting debt burden.
Lack of Focus on Long-Term Value Creation: Valeant prioritized short-term financial engineering over sustainable, long-term value creation. The company focused on cost-cutting measures, price hikes on existing drugs, and aggressive accounting practices to boost short-term profits, rather than investing in research and development or organic growth initiatives.
Opaque Business Practices: Valeant's business model and accounting practices were criticized for their lack of transparency and disclosure. The company faced scrutiny over its drug pricing policies, distribution practices, and relationships with specialty pharmacies, which raised concerns among investors and regulators about the sustainability and legitimacy of its business operations.
Erosion of Stakeholder Trust: Valeant's controversial business practices and governance issues eroded stakeholder trust and damaged its reputation in the pharmaceutical industry and financial markets. The company faced legal and regulatory investigations, shareholder lawsuits, and a sharp decline in its stock price, ultimately resulting in significant financial losses for investors.
In light of the Valeant debacle, it's crucial for companies to approach acquisition strategies with prudence, diligence, and a focus on long-term value creation. While acquisitions can be a viable means of driving growth and enhancing shareholder value, they should be pursued in a strategic manner, with careful consideration of factors such as integration risks, financial sustainability, cultural alignment, and ethical implications.
Companies should prioritize transparency, accountability, and ethical conduct in their business practices to maintain stakeholder trust and mitigate the potential risks associated with aggressive growth strategies. Learning from the mistakes of companies like Valeant, organizations can develop more robust acquisition strategies that prioritize sustainable growth and value creation over short-term financial engineering.
PLAYBOOK: How to evaluate M&A opportunities differently from a Valeant
Let's compare and contrast the discussion about M&A strategies for growth with the case of Valeant Pharmaceuticals:
Approach to Acquisitions:
In our existing conversation, we discussed the strategy of acquiring multiple companies with long-dated revenue streams as a means to diversify risk, access new markets, and drive sustainable growth. This approach emphasizes disciplined capital allocation and strategic acquisitions aimed at long-term value creation.
In the case of Valeant Pharmaceuticals, the company pursued an aggressive acquisition strategy focused on rapid growth through acquisitions. However, Valeant's approach was criticized for its lack of transparency, reliance on financial engineering, and neglect of long-term value creation in favor of short-term profit maximization.
Risk Management:
Our discussion highlighted the importance of risk management in M&A transactions, particularly the need for thorough due diligence, integration planning, and consideration of potential risks and challenges.
Valeant's approach to acquisitions was characterized by a high level of risk-taking, as the company accumulated significant debt to finance its acquisition spree without adequately addressing integration challenges or assessing the long-term viability of its business model.
Value Creation:
Our conversation emphasized the importance of creating value through strategic acquisitions that enhance revenue streams, drive synergies, and foster long-term growth. This approach prioritizes sustainable value creation and stakeholder alignment.
Valeant's pursuit of short-term profit maximization through aggressive cost-cutting measures, price hikes, and financial engineering ultimately undermined its long-term value creation potential and eroded stakeholder trust.
Transparency and Governance:
We've discussed the significance of transparency, accountability, and ethical conduct in M&A transactions, highlighting the importance of maintaining stakeholder trust and adhering to regulatory standards.
Valeant Pharmaceuticals faced criticism and legal scrutiny over its opaque business practices, questionable accounting methods, and lack of transparency in its drug pricing and distribution strategies, which contributed to a loss of credibility and investor confidence.
In summary, while our conversation focused on the strategic benefits of M&A transactions for growth and value creation, the case of Valeant Pharmaceuticals serves as a cautionary example of the risks associated with aggressive acquisition strategies pursued without proper diligence, transparency, and long-term sustainability considerations.
Phew! Return to organic growth!:
As market uncertainties decrease and competition dwindles, there could be a shift back to organic growth. The current environment, filled with unknowns (such as unpredictable policy changes and market volatility), makes acquisitions a safer growth strategy in the short term. However, a balanced approach that includes a return to organic growth can be more sustainable long-term.
Here are some potential opportunities to accomplish the above:
Increase in Disease Prevalence and Medication Use: As noted, the prevalence of chronic diseases and mental health issues is rising. According to the Centers for Disease Control and Prevention (CDC), six in ten Americans live with at least one chronic disease. Moreover, the National Institute of Mental Health reports that nearly one in five U.S. adults lives with a mental illness. Highlighting these statistics stresses the ongoing need for innovative healthcare solutions and strategic acquisitions that address these growing healthcare demands.
Total Cost of Care Savings: Differentiate the provider & pharmaceutical industry from others by focusing on the total cost of care savings. Strategic acquisitions can lead to enhanced data governance & analytics, synergistic payer case mgmt. and provider/PBM care mgmt., better data governance & collaboration can improve drug efficacy and accessibility (prior-auth); reducing long-term healthcare costs. For example, acquiring companies that focus on preventative treatments or specialized therapies can reduce the overall burden of disease management and streamline prior-authorizations, reducing administrative burden on all parties.
A New Hope (Part GLP-1):
Expanding your acquisition reach (for example to a GLP-1 manufacturer) can allow for control of these burgeoning economics. This would be a non-traditional acquisition for most healthcare organizations but the upside is very tenable (as early in the game as possible!)
1) GLP-1 Impact on Managed Care Economics: GLP-1 agonists like semaglutide (marketed as Ozempic, Rybelsus, and Wegovy) have demonstrated significant benefits in weight management and glycemic control, which has led to a rapid increase in their demand. This growing usage can lead to cost savings for managed care organizations by reducing complications associated with obesity and diabetes, such as cardiovascular diseases and stroke, thereby decreasing long-term healthcare expenses.
2) Market Demand and Pricing: The popularity of GLP-1 treatments has also introduced new dynamics in pricing and insurance coverage. Managed care organizations are now more likely to negotiate favorable terms with manufacturers to include these drugs in their formularies due to their potential to reduce hospital admissions and other costly medical interventions.
3) Investment in Research and Development: The success of GLP-1 therapies has spurred increased investment in research and development within the pharmaceutical industry, focusing on similar peptide-based therapies that can address a broad range of metabolic disorders. This trend is influencing merger and acquisition strategies, as companies seek to acquire firms with promising pipelines in peptide therapeutics to capitalize on this growing market.
4) Strategic Acquisitions and Partnerships: Pharmaceutical companies are increasingly looking to acquire smaller biotech firms that specialize in GLP-1 related therapies or form strategic partnerships to expand their portfolio in this area. These strategic partnerships CAN be substituted by non-traditional acquisition.
These moves are not only financially motivated but are also driven by the need to meet the rising demand for highly effective and cost-efficient chronic disease management solutions.
5) Long-Term Market Effects: The popularity of GLP-1 agonists is reshaping long-term market strategies in the pharmaceutical industry. Companies are reassessing their product lines and investment in chronic disease management, expecting that the success of these drugs will increase patient and provider expectations for similar outcomes in other therapeutic areas.
My purpose is to highlight the transformative impact of GLP-1 agonists on the healthcare landscape, particularly concerning managed care economics and strategic corporate actions. Emphasizing the importance of staying at the forefront of medical innovation to drive both health outcomes and economic efficiency in the healthcare system is a must and can be done by non-traditional acquisition of these cash cow companies and benefiting from the 4 levers we mentioned at the top.
A New Hope (Part 2 - Part C & D):
Exploring long-term solutions to improve the sustainability and affordability of healthcare, particularly in pharmaceuticals, is crucial. Non-vertically integrated acquisitions or partnerships (whether an ACO, PBM or payer), when it comes with immediate accretive value to income statement and balance sheet, can have returns potential explode with the right governance.
Reducing Patent Lengths on Specialty Drugs: Shorter patent exclusivities for specialty drugs could foster competition more quickly, allowing generic and biosimilar drugs to enter the market sooner. This can reduce drug prices and make treatments more accessible to a broader population.
Federal Direct Caps on Prescription Costs: Implementing federal regulations to cap prescription drug costs could directly control price inflation. Caps can be adjusted based on therapy novelty, treatment necessity, and public health impact to ensure fair compensation for innovation while protecting patients from excessive pricing.
Enhanced Public Data Sharing: Establishing a more robust framework for the sharing of longitudinal public health data can improve research and development efficiencies and foster public-private partnerships. This approach would help identify health trends faster, improve patient outcomes through more tailored therapies, and reduce redundant spending in R&D.
Reduction in Broker Commissions: Lowering commissions for pharmacy benefit managers (PBMs) and brokers can decrease the overall cost of drugs. Ensuring that a larger portion of healthcare dollars is spent directly on patient care rather than intermediary fees could enhance the value received by patients and payers.
Virtual Health Steerage and Incentives: Encouraging the use of virtual health platforms through financial incentives can steer patients towards more cost-effective care options. Virtual health can reduce unnecessary in-person visits, streamline chronic disease management, and improve patient engagement and outcomes.
Use of Financial Instruments Like Reinsurance: Expanding the use of reinsurance to cover high-cost claims can reduce the financial risk associated with expensive treatments. This strategy can stabilize insurance markets and lower premiums, making health insurance more affordable for a broader base of consumers.
Value-Based Pricing Models: Transitioning more extensively to value-based pricing, where drug costs are tied to their clinical outcomes, can align drug prices more closely with their actual value to patients. This could incentivize pharmaceutical companies to focus on high-impact, innovative treatments.
Streamlined Approval Processes for Generic and Biosimilar Drugs: Simplifying regulatory pathways for generics and biosimilars can accelerate their market entry. This would enhance competition, lower drug prices, and increase accessibility.
Expansion of Preventive and Early Intervention Care: Investing more in preventive measures and early intervention for chronic diseases can reduce the long-term dependency on pharmaceutical solutions. This strategy not only improves public health but also decreases the overall healthcare burden.
Public-Private Partnerships for Drug Development: Encouraging collaborative drug development initiatives between government entities and private companies can spread financial risk, reduce individual investment burden, and pool resources for R&D, leading to more innovative and cost-effective healthcare solutions.
A New Hope (Provider JVs, Delegated UM/CM, & strategic alignment with drivers of cost attributed to doctors):
Joint ventures between payer/benefit mgmt. UM+CM and provider groups/CINs, offer another strategic avenue to explore. This approach can help consolidate the right data, streamline patient access, improves quality, enhances experience through aligned incentives and ultimately, lower costs. Here’s how to frame your analysis:
Shared Investment and Risks: Joint ventures allow streamlined patient access to goods and services but also enable more universal data access (w/ right governance) through shared, scaled investments into functions that benefit all parties, reduce admin burdens and streamline access. These partnerships also create possibilities to delegate UM/CM/DM and reduce redundant medical management. Shared risks and incentives, together lay the path to truly minimizing administrative burden in MA. Including non-traditional orgs. like drug developers or other healthcare service companies attempting to innovate to improve their cost of doing business, as strategic partners with financial skin in-the-game, is a great prospect. This can lead to more sustainable financial models, especially in areas of high research and development costs or where market returns are uncertain.
Improved Access to Innovative Treatments: By collaborating, streamlined administrative ops can improve patient access to the latest treatments. One might even argue, a triumverate org. arrangement of income generating entities across the healthcare spectrum would reduce bad-debt, lower TCoC, improve access & quality and overall MA economics. Such a triumvirate (e.g. payer, provider, manufacturer) often have extensive networks that can facilitate broader distribution and quicker adoption of new drugs and therapies within their systems, benefiting patient populations with cutting-edge care.
Enhanced Drug Development Through Real-World Data: Healthcare providers can offer valuable real-world data from a diverse patient base, which can be instrumental in the drug development process. This data helps in understanding drug effectiveness and safety in broader, more varied populations, potentially speeding up the approval process and tailoring drug development to meet specific health outcomes.
Streamlined Processes and Reduced Costs: Joint ventures can streamline various processes such as clinical trials, patient recruitment, and regulatory compliance by pooling resources like data, reducing admin hurdles, and sharing capabilities. This not only reduces costs but also enhances the speed and efficiency of bringing drugs to market.
Coordinated Care Models: Through joint ventures, pharmaceutical companies can work closely with providers to develop coordinated care models that integrate drug therapies seamlessly into comprehensive treatment plans. This can improve treatment adherence, patient outcomes, and overall satisfaction.
Incentive Alignment: Consolidating providers and pharmaceutical (OR PBMs, more realistically) companies can align incentives more closely through joint ventures. For example, they can tie financial outcomes to patient health outcomes, encouraging innovations that genuinely enhance patient care and system efficiency rather than focusing solely on profitability.
Market Expansion and Diversification: Collaborations between these entities can also help both parties expand into new markets and patient demographics, diversify their portfolios, and reduce dependence on a single market segment.
Enhanced Negotiating Power with Payers: A joint venture can increase negotiating power with insurance companies and payers, potentially securing better reimbursement rates for new therapies by demonstrating improved patient outcomes and cost savings.
Incorporating joint ventures may be a proactive approach to overcoming the challenges in the healthcare industry by leveraging synergies between benefit managers and healthcare providers. This strategy points toward a future where collaborative efforts lead to more efficient and effective healthcare delivery systems.
A New Hope (MA & Provider Collab.):
Adding the benefits of delegated and accelerated utilization management (UM) processes for Medicare Advantage Plans (Part C) and Prescription Drug Plans (Part D) can further strengthen the argument for joint ventures and collaborations between pharmaceutical companies and healthcare providers:
Enhanced Efficiency of Utilization Management: Delegated UM allows provider groups or managed care organizations to handle pre-authorizations, claims adjudications, and benefit determinations directly. This can significantly speed up the process, reducing the time and bureaucracy typically involved in accessing necessary medical services and medications.
Improved Patient and Provider Experience: Faster UM processes, particularly in Medicare Advantage and Part D plans, can lead to a better overall experience for both patients and providers. Patients benefit from quicker access to necessary treatments without lengthy waits for approval, which can be crucial for chronic conditions commonly found in the Medicare population.
Cost Savings and Resource Allocation: By streamlining UM processes, joint ventures can reduce administrative costs and reallocate resources towards more patient-centric activities, such as preventive care and chronic disease management. This not only improves care but also reduces overall healthcare costs by minimizing complications and hospitalizations.
Data-Driven Decision Making: Accelerated UM can leverage data analytics to make more informed and timely decisions about care appropriateness and necessity. This integration of data-driven insights enhances the accuracy of UM decisions, aligns them more closely with patient needs, and improves health outcomes.
Alignment with Regulatory Requirements: Medicare Advantage and Part D plans are subject to stringent regulatory requirements that mandate timely access to covered services and drugs. Improved UM processes ensure compliance with these regulations, reducing the risk of penalties and improving patient satisfaction scores.
Collaborative Care Approaches: In a joint venture setting, pharmaceutical companies and healthcare providers can collaborate more effectively on care protocols and guidelines, ensuring that UM decisions support the most appropriate and effective use of medications and therapies.
Innovative Contracting: Faster UM processes facilitated through joint ventures can support innovative contracting models like value-based arrangements, where reimbursement is tied to patient outcomes. This aligns the economic incentives of providers and payers with the health outcomes of patients, promoting the use of the most effective and efficient treatments.
By emphasizing the role of delegated and accelerated UM processes in Medicare Advantage and Part D plans within the framework of joint ventures, we are highlighting practical opportunities to improve the efficiency and effectiveness of healthcare delivery. This occurs by reducing administrative burden and barriers to the right data needed. These improvements are essential for adapting to the evolving needs of the healthcare market and the growing Medicare population.
A New Hope (Rapid Innovation):
It's essential to consider several factors. Here's a structured way to present this argument:
Improvements in Drug Development: Marginally smarter drug development involves using advanced technologies such as artificial intelligence, machine learning, and genomics to improve the precision and efficiency of drug discovery and development. These technologies can significantly reduce the time and cost of bringing new drugs to market by better predicting drug efficacy and safety profiles. For instance, McKinsey estimates that leveraging big data and AI in pharmaceutical R&D could generate up to $100 billion annually across the US healthcare system, through improvements in innovation, reduced trial times, and better patient selection for trials.
Enhanced Clinical Therapies: The integration of precision medicine and targeted therapies can substantially improve the effectiveness of clinical treatments. By focusing on the underlying mechanisms of diseases and individual patient characteristics, these therapies can reduce the incidence of adverse drug reactions and increase treatment efficacy. According to a study by the Personalized Medicine Coalition, targeted therapies have shown to increase response rates in patients by up to 50% compared to standard treatments. This directly translates to cost savings by reducing wasted expenditures on ineffective therapies and lowering the rates of hospital readmissions.
Surgical Innovations: Advancements in surgical techniques, such as minimally invasive surgeries and robotic-assisted procedures, have been shown to reduce hospital stay lengths, lower infection rates, and decrease postoperative recovery times. A report from the American Hospital Association indicated that minimally invasive surgeries can reduce patient hospital stays by up to 50%, leading to substantial cost savings for healthcare systems. Additionally, these advancements contribute to a quicker return to productivity for patients, indirectly reducing economic losses from illness.
Enhanced Diagnostic Accuracy: AI can significantly improve the accuracy and speed of medical diagnostics. For example, AI algorithms are capable of analyzing complex medical images, such as MRIs and CT scans, with a higher degree of accuracy than sometimes even experienced radiologists. This reduces misdiagnoses and unnecessary treatments, which are costly and can delay appropriate care.
Personalized Treatment Plans: Advanced analytics and AI enable the development of highly personalized medicine by analyzing vast amounts of data from genetic information, lifestyle, and previous health records to predict the most effective treatment strategies for individual patients. This not only increases the efficacy of treatments but also minimizes the risk of side effects and adverse reactions, leading to more efficient healthcare delivery and reduced costs.
Optimization of Clinical Trials: AI can streamline the clinical trial process by improving patient selection through predictive analytics, thus increasing the likelihood of successful trial outcomes. This technology also helps in monitoring trial progress in real time, identifying potential issues early, and reducing the duration and cost of trials. For instance, AI-driven simulations can predict how drugs interact with the body, reducing the need for some lengthy and expensive clinical trials.
Operational Efficiencies: AI-driven tools and automation can enhance operational efficiencies in healthcare facilities. For example, AI can optimize scheduling, patient flow, inventory management, and administrative tasks, freeing up healthcare professionals to focus more on patient care and reducing overhead costs.
Drug Development and Repurposing: AI technologies are being used to identify new therapeutic uses for existing medications, a process known as drug repurposing, which can significantly reduce the time and cost associated with bringing a drug to market. AI models that predict how drugs interact at the molecular level can uncover new applications for old drugs, speeding up the innovation cycle and extending the profitable life of pharmaceutical assets.
Predictive Healthcare: With the aid of machine learning models, healthcare providers can predict patient risks and disease progression more accurately. Predictive analytics can alert providers and patients about potential health issues before they become serious, promoting preventative care measures that save costs associated with acute and emergency care.
Scale and Accessibility: Exponential technologies enable healthcare solutions to scale rapidly and become more accessible. Telemedicine, powered by AI for initial diagnosis and patient monitoring, extends healthcare's reach, particularly to underserved or remote areas, reducing travel and infrastructure costs.
Comprehensive Savings Estimate: By combining these advancements, the overall potential for cost savings is substantial. If smarter drug development reduces drug development costs by 10-20%, and more effective therapies and surgeries improve treatment outcomes and reduce hospitalizations by even 10-15%, the healthcare system could see a reduction in annual expenditures by billions of dollars. For example, considering the total healthcare expenditure in the U.S., which was about $4 trillion in 2020, even a 5% reduction in costs due to these improvements could translate to savings of $200 billion annually.
Long-term Impacts: Beyond immediate cost savings, these improvements can lead to a healthier population with less reliance on acute and chronic care, further bending the cost curve downward over time. Preventive measures and early interventions facilitated by smarter therapies will decrease the need for more intensive health services, which are often costlier.
Hopefully we have outlined a meaningfully comprehensive view of how marginally smarter drug development, more effective clinical therapies, and innovative surgical techniques can collectively contribute to significant cost savings in healthcare. This approach not only underscores the importance of technological and procedural advancements but also aligns with broader economic and policy objectives in healthcare.
Conclusion:
In conclusion, navigating the challenges faced by Medicare Advantage managed care plans in today's tumultuous environment requires innovative and strategic approaches. The proposed alternative strategic M&A strategy, focusing on acquiring long-dated revenue companies, presents a viable path to fuel growth and create value. By prioritizing acquisitions that offer steady revenue streams, accretive value economics, non-vertical integration, and sweat equity potential, managed care organizations can achieve resilience and sustainable growth.
Diversifying through multiple smaller acquisitions rather than pursuing blockbuster deals can mitigate risks, enhance scalability, and broaden market penetration. This approach aligns with the principles outlined in William N. Thorndike's "The Outsiders," where disciplined capital allocation and strategic acquisitions lead to long-term success. However, it is crucial to learn from past mistakes, such as the Valeant Pharmaceuticals debacle, by ensuring thorough due diligence, transparency, and a focus on long-term value creation.
Moreover, as market uncertainties decrease, a balanced approach that includes a return to organic growth should be considered. Strategic investments in disease prevalence and medication use, total cost of care savings, and leveraging advancements in GLP-1 therapies, benefit management, and provider collaboration models can further drive innovation and efficiency in healthcare delivery.
Ultimately, embracing a combination of strategic M&A and organic growth, supported by innovative practices and robust governance, can help managed care organizations thrive in an ever-evolving landscape. This multifaceted strategy not only addresses immediate challenges but also positions organizations for sustained success and value creation for stakeholders.
Comments